- Home
- QS vs APGE Comparison
QS vs APGE Comparison
Compare QS & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QS | APGE |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 4.7B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | QS | APGE |
|---|---|---|
| Price | $11.83 | $76.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $9.06 | ★ $100.00 |
| AVG Volume (30 Days) | ★ 17.6M | 757.0K |
| Earning Date | 10-22-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $26.20 |
| 52 Week High | $19.07 | $78.12 |
Technical Indicators
Market Signals| Indicator | QS | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 72.83 |
| Support Level | $11.57 | $74.00 |
| Resistance Level | $13.00 | $76.87 |
| Average True Range (ATR) | 0.64 | 3.40 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 27.70 | 87.77 |
Price Performance
Historical ComparisonAbout QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.